A carregar...
Hydroxyurea Use in Children with Sickle Cell Disease: Do Severely Affected Patients Use It and Does It Impact Hospitalization Outcomes?
BACKGROUND: Expert guidelines recommend that hydroxyurea (HU) be offered to all children with Hemoglobin SS and Sβ(0) sickle cell disease (SCD) and be considered for children with clinically severe Hemoglobin SC or Sβ(+). This study aims to determine the rate of HU use in hospitalized children, if H...
Na minha lista:
| Publicado no: | Pediatr Blood Cancer |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4801693/ https://ncbi.nlm.nih.gov/pubmed/26797936 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.25894 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|